Brief: Greenwich Lifesciences Confirms FDA Reviewed Co's Mid-Stage Clinical Data Before The Commencement Of The Flamingo-01 Clinical Trial
13/04/2023 12:11
April 13 (Reuters) - Greenwich Lifesciences Inc
GLSI.O :
* GREENWICH LIFESCIENCES INC - CO CONFIRMS FDA REVIEWED CO'S
PHASE
IIB CLINICAL DATA BEFORE THE COMMENCEMENT OF THE FLAMINGO-01
CLINICAL TRIAL
* GREENWICH LIFESCIENCES INC - CO CONFIRMS COMPANY IS
PLANNING AN
EXPANSION OF THE FLAMINGO-01 CLINICAL TRIAL INTO EUROPE
Source text : (https://bit.ly/41oEwQx)
Further company coverage: GLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio